Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 390

Similar articles for PubMed (Select 21953021)

1.

A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.

Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, Pharoah PD, Caldas C.

J Pathol. 2012 Jan;226(1):97-107. doi: 10.1002/path.2976. Epub 2011 Sep 26.

PMID:
21953021
2.

Aurora kinase A outperforms Ki67 as a prognostic marker in ER-positive breast cancer.

Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C.

Br J Cancer. 2012 May 22;106(11):1798-806. doi: 10.1038/bjc.2012.167. Epub 2012 Apr 26.

3.

Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.

Rexhepaj E, Jirstrom K, O'Connor DP, O'Brien SL, Landberg G, Duffy MJ, Brennan DJ, Gallagher WM.

BMC Cancer. 2010 Nov 23;10:639. doi: 10.1186/1471-2407-10-639.

4.

The prognostic value of Ki67 is dependent on estrogen receptor status and histological grade in premenopausal patients with node-negative breast cancer.

Klintman M, Bendahl PO, Grabau D, Lövgren K, Malmström P, Fernö M; South Sweden Breast Cancer Group.

Mod Pathol. 2010 Feb;23(2):251-9. doi: 10.1038/modpathol.2009.167. Epub 2009 Nov 20.

5.

Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index.

Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, Ellis IO, Huntsman D, Caldas C.

Clin Cancer Res. 2006 Apr 15;12(8):2468-75. Erratum in: Clin Cancer Res. 2006 Aug 15;12(16):5002.

6.

BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received.

Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, Baglietto L, Severi G, Giles GG, McLean CA, Callagy G, Green AR, Ellis I, Gelmon K, Turashvili G, Leung S, Aparicio S, Huntsman D, Caldas C, Pharoah P.

Br J Cancer. 2010 Aug 24;103(5):668-75. doi: 10.1038/sj.bjc.6605736. Epub 2010 Jul 27. Erratum in: Br J Cancer. 2010 Sep 28;103(7):1137.

7.

Cancer stem cell markers in breast cancer: pathological, clinical and prognostic significance.

Ali HR, Dawson SJ, Blows FM, Provenzano E, Pharoah PD, Caldas C.

Breast Cancer Res. 2011;13(6):R118. doi: 10.1186/bcr3061. Epub 2011 Nov 23.

8.

COX2 overexpression is a prognostic marker for Stage III breast cancer.

Kim HS, Moon HG, Han W, Yom CK, Kim WH, Kim JH, Noh DY.

Breast Cancer Res Treat. 2012 Feb;132(1):51-9. doi: 10.1007/s10549-011-1521-3. Epub 2011 Apr 28.

PMID:
21533532
9.

Proposal for a modified grading system based on mitotic index and Bcl2 provides objective determination of clinical outcome for patients with breast cancer.

Abdel-Fatah TM, Powe DG, Ball G, Lopez-Garcia MA, Habashy HO, Green AR, Reis-Filho JS, Ellis IO.

J Pathol. 2010 Dec;222(4):388-99. doi: 10.1002/path.2775.

PMID:
20922713
10.

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.

Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M.

J Natl Cancer Inst. 2008 Oct 1;100(19):1380-8. doi: 10.1093/jnci/djn309. Epub 2008 Sep 23.

11.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.

12.

Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypes.

Yerushalmi R, Gelmon KA, Leung S, Gao D, Cheang M, Pollak M, Turashvili G, Gilks BC, Kennecke H.

Breast Cancer Res Treat. 2012 Feb;132(1):131-42. doi: 10.1007/s10549-011-1529-8. Epub 2011 May 15.

PMID:
21574055
13.

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.

Breast Cancer Res. 2008;10(5):R86. doi: 10.1186/bcr2156. Epub 2008 Oct 16.

14.

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.

Breast Cancer Res. 2008;10(5):R74. doi: 10.1186/bcr2139. Epub 2008 Sep 4.

15.

The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.

Pathmanathan N, Balleine RL, Jayasinghe UW, Bilinski KL, Provan PJ, Byth K, Bilous AM, Salisbury EL, Boyages J.

J Clin Pathol. 2014 Mar;67(3):222-8. doi: 10.1136/jclinpath-2013-201793. Epub 2014 Jan 8.

PMID:
24403187
16.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
17.

MDM2 protein expression is a negative prognostic marker in breast carcinoma.

Turbin DA, Cheang MC, Bajdik CD, Gelmon KA, Yorida E, De Luca A, Nielsen TO, Huntsman DG, Gilks CB.

Mod Pathol. 2006 Jan;19(1):69-74.

18.

Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.

Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A.

Breast Cancer Res Treat. 2010 Dec;124(3):607-17. doi: 10.1007/s10549-010-0761-y. Epub 2010 Feb 3.

PMID:
20127405
19.

Prognostic relevance of activated Akt kinase in node-negative breast cancer: a clinicopathological study of 99 cases.

Schmitz KJ, Otterbach F, Callies R, Levkau B, Hölscher M, Hoffmann O, Grabellus F, Kimmig R, Schmid KW, Baba HA.

Mod Pathol. 2004 Jan;17(1):15-21.

20.

Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer.

Jögi A, Brennan DJ, Rydén L, Magnusson K, Fernö M, Stål O, Borgquist S, Uhlen M, Landberg G, Påhlman S, Pontén F, Jirström K.

Mod Pathol. 2009 Dec;22(12):1564-74. doi: 10.1038/modpathol.2009.124. Epub 2009 Sep 4.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk